RxDoctor Payments Data

Shilpa Iyer

Urogynecology and Reconstructive Pelvic Surgery · Chicago, ILNPI 1508181140

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,614 of the $2,463 with a category attached, or 65.5%. 9 manufacturers reported payments, led by Medtronic at 56.4% of the total. Reporting peaked in 2022 at $1,391 and has fallen 84.4% since, to $217 in 2025. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in IL, where the typical reported total is $2,778.

$2,463in general payments, 2019–2025

Across 33 payments — averaging $74.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Boston Scientific$767
  • Applied Medical Resources Corporation$108
  • Ferring Pharmaceuticals Inc.$87
  • Axonics, Inc.$31
  • AbbVie$26
  • plus $55 from 3 others

What the payments were for

  • Travel & lodging$84934%
  • Food & beverage$1,61466%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,463 in reported general payments places this provider in the 45th percentile of 62 urogynecology and reconstructive pelvic surgery providers in Illinois.

See all urogynecology and reconstructive pelvic surgery providers in Illinois

Medicare billing

Part B allowed, 2024
$75,400
Medicare patients
163
Services billed
2,770

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron264$146,992
GemtesaVibegron107$67,151
Estradiol118$7,323
Solifenacin Succinate143$6,812
PremarinEstrogens, Conjugated13$6,630
NitrofurantoinNitrofurantoin Macrocrystal138$3,298
Oxybutynin Chloride ErOxybutynin Chloride56$1,190
Fesoterodine Fumarate ErFesoterodine Fumarate18$987
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst82$850
Methenamine Hippurate17$751
Trospium Chloride18$347
Amitriptyline Hcl43$161
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim15$105
Cephalexin14$84
Ibuprofen11$78

Paid to pharmacies, not to this prescriber.

Other urogynecology and reconstructive pelvic surgery in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →